DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Auryxia" drug pipelines has been added to ResearchAndMarkets.com's offering.
Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease. The drug dissociates into ferric iron and citrate after administration. Ferric iron is transported to erythroid precursor cells to be incorporated into hemoglobin, and also binds dietary phosphate in the gastrointestinal tract, precipitating as ferric phosphate. This compound is excreted, decreasing the phosphate concentration in the serum.
Key Topics Covered:
Product Profiles
Auryxia: Anemia in chronic kidney disease
List of Figures
Figure 1: Auryxia for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of Auryxia for anemia in chronic kidney disease (1)
Figure 3: Drug assessment summary of Auryxia for anemia in chronic kidney disease (2)
Figure 4: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
List of Tables
Table 1: Auryxia drug profile
Table 2: Auryxia Phase III data in anemia in chronic kidney disease
Table 3: Auryxia Phase II data in anemia in chronic kidney disease
Table 4: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ttpdw5/auryxia_global?w=4
